Physician profile
Peter D Jurisich
NPI 1629083407
$19,371.20
in general payments reported to CMS, 2019-2025
28 companies · $6,056 in 2025
The $6,056 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,893 · 2020: $2,679 · 2021: $2,230 · 2022: $2,412 · 2023: $893 · 2024: $2,207 · 2025: $6,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,113 · Food and Beverage: $4,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,113.06 |
| Food and Beverage | $4,043.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,043.00 | 2021-2025 | Micra, Attain Command + Surevalve, Cardioblate Cryoflex |
| Abbott Laboratories | $3,546.17 | 2019-2025 | Aveir, Ensite, Tacticath Ablation Catheter, Sensor Enabled |
| Biosense Webster, INC. | $3,507.97 | 2021-2025 | Carto 3, Qdot Micro Catheter, Octaray Mapping Catheter |
| Medtronic Vascular, INC. | $2,778.79 | 2019-2020 | |
| Boston Scientific Corporation | $2,255.42 | 2021-2025 | Farapulse, Rhythmia Mapping System |
| Acutus Medical, INC. | $620.00 | 2019-2021 | |
| Biotronik INC. | $533.26 | 2019-2025 | Acticor 7 Vr-T Dx |
| Janssen Pharmaceuticals, INC | $382.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $296.70 | 2019-2021 | |
| Atricure, INC. | $178.73 | 2024 | |
| Edwards Lifesciences Corporation | $158.70 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $151.32 | 2019-2022 | |
| Cardiva Medical, INC. | $144.85 | 2022 | |
| Amgen INC. | $138.88 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.13 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $77.38 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.15 | 2019-2021 | |
| Amarin Pharma, INC. | $59.68 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.92 | 2021 | |
| W. L. Gore & Associates, INC. | $44.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.95 | 2019 | |
| Merck Sharp & Dohme LLC | $39.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $37.21 | 2020-2021 | |
| Pfizer INC. | $35.69 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.72 | 2019-2021 | |
| Heartflow, INC. | $29.53 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.14 | 2021 | |
| Esperion Therapeutics, INC. | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Jurisich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.